OTCPK:OZSC

Stock Analysis Report

Executive Summary

Ozop Surgical Corp. engages in the inventing, designing, developing, manufacturing, and distributing innovative endoscopic instruments, surgical implants, instrumentation, devices, and related technologies for spine, neurological, and pain management procedures and specialties in the United States and Hong Kong.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • Ozop Surgical has significant price volatility in the past 3 months.
  • Ozop Surgical is not covered by any analysts.

Share Price & News

How has Ozop Surgical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

40.0%

OZSC

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

n/a

OZSC

9.5%

US Medical Equipment

1.1%

US Market

No trading data on OZSC.

No trading data on OZSC.


Share holder returns

OZSCIndustryMarket
7 Day40.0%0.7%-0.2%
30 Day-52.2%0.1%2.5%
90 Day-56.9%2.5%1.6%
1 Yearn/a10.4%9.5%3.4%1.1%
3 Yearn/a69.3%64.1%45.2%35.8%
5 Yearn/a138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is Ozop Surgical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Ozop Surgical undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Ozop Surgical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Ozop Surgical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of OZSC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Ozop Surgical regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Ozop Surgical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ozop Surgical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of OZSC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Ozop Surgical's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Ozop Surgical performed over the past 5 years?

-156.6%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Ozop Surgical does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Ozop Surgical's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Ozop Surgical's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Ozop Surgical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Ozop Surgical has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Ozop Surgical improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is Ozop Surgical's financial position?


Financial Position Analysis

Ozop Surgical's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Ozop Surgical has no long term commitments.


Debt to Equity History and Analysis

Ozop Surgical has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Ozop Surgical's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

Ozop Surgical has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Ozop Surgical has less than a year of cash runway based on current free cash flow.

Ozop Surgical has less than a year of cash runway if free cash flow continues to grow at historical rates of 46.3% each year.


Next Steps

Dividend

What is Ozop Surgical's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Ozop Surgical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Ozop Surgical's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Ozop Surgical has not reported any payouts.

Unable to verify if Ozop Surgical's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Ozop Surgical has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Ozop Surgical's salary, the management and board of directors tenure and is there insider trading?

1.4yrs

Average management tenure


CEO

Michael Chermak (60yo)

1.4yrs

Tenure

US$140,885

Compensation

Mr. Michael D. Chermak is Chief Executive Officer and Chairman of the Board of Ozop Surgical Corp since April 13, 2018 nd served as Director. Mr. Chermak serves as the Chief Executive Officer, President an ...


CEO Compensation Analysis

Michael's remuneration is lower than average for companies of similar size in United States of America.

Michael's compensation has increased whilst company is loss making.


Management Age and Tenure

1.4yrs

Average Tenure

61yo

Average Age

The average tenure for the Ozop Surgical management team is less than 2 years, this suggests a new team.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Barry Hollander (62yo)

    Chief Financial Officer

    • Tenure: 1.4yrs
    • Compensation: US$120.00k
  • Michael Chermak (60yo)

    CEO & Chairman of the Board

    • Tenure: 1.4yrs
    • Compensation: US$140.89k
  • Tom McLeer (62yo)

    COO & Director

    • Tenure: 0.5yrs
  • Nick Ansari (58yo)

    Executive Vice President of Sales & Marketing

    • Tenure: 0yrs

Board Members

  • Michael Chermak (60yo)

    CEO & Chairman of the Board

    • Tenure: 1.4yrs
    • Compensation: US$140.89k
  • Tom McLeer (62yo)

    COO & Director

    • Tenure: 0.5yrs

Company Information

Ozop Surgical Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ozop Surgical Corp.
  • Ticker: OZSC
  • Exchange: OTCPK
  • Founded: 2015
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$548.025k
  • Shares outstanding: 39.14m
  • Website: https://www.ozopsurgical.com

Location

  • Ozop Surgical Corp.
  • 319 Clematis Street
  • Suite 714
  • West Palm Beach
  • Florida
  • 33401
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OZSCOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDApr 2018

Biography

Ozop Surgical Corp. engages in the inventing, designing, developing, manufacturing, and distributing innovative endoscopic instruments, surgical implants, instrumentation, devices, and related technologies ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 01:09
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.